Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Advanced Medical Emergency Department and Critical Care Center, Japan Red Cross Maebashi Hospital, Maebashi, Japan.
Resuscitation. 2019 Jul;140:135-141. doi: 10.1016/j.resuscitation.2019.05.028. Epub 2019 May 30.
There are no established risk classification for post-cardiac arrest syndrome (PCAS) patients at the Emergency Department (ED) undergoing targeted temperature management (TTM). The aim of this study was to externally validate a simplified version of our prognostic score, the "post-Cardiac Arrest Syndrome for Therapeutic hypothermia score" (revised CAST [rCAST]) and estimate the predictive accuracy of the risk classification based on it.
For the external validation, we used data from an out-of-hospital cardiac arrest (OHCA) registry of the Japanese Association for Acute Medicine (JAAM), which is a multicenter, prospective registry of OHCA patients across Japan. Eligible patients were PCAS patients treated with TTM at 33-36 °C between June 2014 and December 2015. We validated the accuracy of rCAST for predicting the neurological outcomes at 30 and 90 days.
Among the 12,024 OHCA patients, the data of 460 PCAS patients treated by TTM were eligible for the validation. The areas under the curve of rCAST for predicting the neurological outcomes at 30 and 90 days were 0.892 and 0.895, respectively. The estimated sensitivity and specificity of the risk categories for the outcomes were as follows: 0.95 (95% CI: 0.92-0.98) and 0.47 (0.40-0.55) for the low (rCAST: ≤5.5), 0.62 (0.56-0.68) and 0.48 (0.40-0.55) for the moderate (rCAST: 6.0-14.0), and 0.57 (0.51-0.63) and 0.95 (0.91-0.98) for the high severity category (rCAST: ≥14.5).
The rCAST was useful for predicting the neurological outcomes with high accuracy in PCAS patients, and the three grades was developed for a risk classification based on the rCAST.
在急诊科(ED)进行目标温度管理(TTM)的心脏骤停后综合征(PCAS)患者中,尚无既定的风险分类。本研究的目的是外部验证我们的预后评分的简化版本,即“心脏骤停后用于治疗性低温的评分”(修订后的 CAST [rCAST]),并估计基于该评分的风险分类的预测准确性。
为了进行外部验证,我们使用了日本急救医学协会(JAAM)的一项院外心脏骤停(OHCA)登记处的数据,该登记处是日本各地 OHCA 患者的多中心、前瞻性登记处。符合条件的患者是在 2014 年 6 月至 2015 年 12 月期间接受 33-36°C TTM 治疗的 PCAS 患者。我们验证了 rCAST 预测 30 天和 90 天神经结局的准确性。
在 12024 例 OHCA 患者中,有 460 例接受 TTM 治疗的 PCAS 患者的数据符合验证标准。rCAST 预测 30 天和 90 天神经结局的曲线下面积分别为 0.892 和 0.895。风险类别对结局的估计敏感性和特异性如下:低风险类别(rCAST:≤5.5)的敏感性和特异性分别为 0.95(95%CI:0.92-0.98)和 0.47(0.40-0.55),中度风险类别(rCAST:6.0-14.0)的敏感性和特异性分别为 0.62(0.56-0.68)和 0.48(0.40-0.55),高风险类别(rCAST:≥14.5)的敏感性和特异性分别为 0.57(0.51-0.63)和 0.95(0.91-0.98)。
rCAST 可用于准确预测 PCAS 患者的神经结局,并且基于 rCAST 开发了三个等级用于风险分类。